Idorsia, aprocitentan, resistant hypertension, PRECISION study, obesity, cardiovascular-kidney-metabolic disease, CKM, endothelin receptor antagonist, blood pressure,

ALLSCHWIL, Switzerland — October 12, 2026 Idorsia Ltd. reported positive findings from two post-hoc analyses of its Phase 3...